Insmed reported $425.49M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
BioMarin Pharmaceutical USD 990M 224M Jun/2026
Cytokinetics USD 28.6M 9.25M Jun/2026
DBV Technologies USD 645K 2.13M Dec/2025
Gilead Sciences USD 7.8B 800M Jun/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Insmed USD 425.49M 119.53M Jun/2026
Novartis USD 13.11B 750M Mar/2026
Regeneron Pharmaceuticals USD 4.29B 690M Jun/2026
Sarepta Therapeutics USD 401.3M 329.5M Jun/2026
Ultragenyx Pharmaceutical USD 214M 78M Jun/2026
Vertex Pharmaceuticals USD 3.33B 340M Jun/2026